[{"id":"b4d402cb-9b95-4ade-8b2a-ba008e6e8258","acronym":"","url":"https://clinicaltrials.gov/study/NCT04234048","created_at":"2021-01-18T20:35:42.430Z","updated_at":"2024-07-02T16:34:26.824Z","phase":"Phase 1","brief_title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04234048","lead_sponsor":"SciTech Development, LLC","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fenretinide nanoparticle (ST-001 nanoFenretinide)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-06-12"},{"id":"2fc1726b-7bbd-4f7d-9a95-7447645c8195","acronym":"","url":"https://clinicaltrials.gov/study/NCT03985072","created_at":"2021-01-18T19:35:56.001Z","updated_at":"2024-07-02T16:36:16.686Z","phase":"Phase 1","brief_title":"Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor","source_id_and_acronym":"NCT03985072","lead_sponsor":"Andes Biotechnologies","biomarkers":" HER-2 • KRAS • NRAS","pipe":" | ","alterations":" RAS wild-type • NRAS wild-type","tags":["HER-2 • KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mulnitorsen (Andes-1537)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 04/26/2019","start_date":" 04/26/2019","primary_txt":" Primary completion: 02/17/2022","primary_completion_date":" 02/17/2022","study_txt":" Completion: 02/17/2022","study_completion_date":" 02/17/2022","last_update_posted":"2022-02-24"},{"id":"dba0e6e2-594f-4f87-9d25-36bb519247e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01240590","created_at":"2021-01-18T04:59:45.037Z","updated_at":"2024-07-02T16:37:23.615Z","phase":"Phase 1/2","brief_title":"A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)","source_id_and_acronym":"NCT01240590","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • crolibulin (EPC2407)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 01/26/2011","start_date":" 01/26/2011","primary_txt":" Primary completion: 08/31/2015","primary_completion_date":" 08/31/2015","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2017-04-10"}]